<?xml version='1.0' encoding='utf-8'?>
<document id="25858508"><sentence text="Mechanism-based inhibition of Alantolactone on human cytochrome P450 3A4 in vitro and activity of hepatic cytochrome P450 in mice."><entity charOffset="30-43" id="DDI-PubMed.25858508.s1.e0" text="Alantolactone" /></sentence><sentence text="Alantolactone (AL), one of the main active ingredients in Inula helenium L"><entity charOffset="0-13" id="DDI-PubMed.25858508.s2.e0" text="Alantolactone" /><entity charOffset="15-17" id="DDI-PubMed.25858508.s2.e1" text="AL" /><pair ddi="false" e1="DDI-PubMed.25858508.s2.e0" e2="DDI-PubMed.25858508.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25858508.s2.e0" e2="DDI-PubMed.25858508.s2.e1" /></sentence><sentence text=", has been included in various prescriptions of traditional Chinese medicine" /><sentence text=" The effects of AL on cytochrome P450 (CYP450) were still unclear"><entity charOffset="16-17" id="DDI-PubMed.25858508.s4.e0" text="AL" /></sentence><sentence text=" This study evaluated the inhibitory effect of AL on cytochrome P450s in vitro and in vivo"><entity charOffset="47-48" id="DDI-PubMed.25858508.s5.e0" text="AL" /></sentence><sentence text="" /><sentence text="The inhibitory effects of AL on the CYPs activity were evaluated in human liver microsomes (HLMs) and recombinant cDNA-expressed enzymes incubation system, and then determined by LC-MS/MS based CYPs probe substrate assay"><entity charOffset="26-27" id="DDI-PubMed.25858508.s7.e0" text="AL" /></sentence><sentence text=" C57BL/6 mice were treated AL orally (0, 25, 50, 100 mg/kg) for 15 days"><entity charOffset="27-28" id="DDI-PubMed.25858508.s8.e0" text="AL" /></sentence><sentence text=" The inhibitory effects of AL on major Cyps in mice were examined at both the mRNA and enzyme activity levels"><entity charOffset="27-28" id="DDI-PubMed.25858508.s9.e0" text="AL" /></sentence><sentence text="" /><sentence text="AL showed a potent inhibitory effect on CYP3A4 activity with IC50 values of 3"><entity charOffset="0-1" id="DDI-PubMed.25858508.s11.e0" text="AL" /></sentence><sentence text="599 (HLMs) and 3" /><sentence text="90 (recombinant CYP3A4) μM, respectively" /><sentence text=" AL strongly decreased CYP3A4 activity in a dose-dependent but not time-dependent way in HLMs"><entity charOffset="1-2" id="DDI-PubMed.25858508.s14.e0" text="AL" /></sentence><sentence text=" Results from typical Lineweaver-Burk plots showed that AL could inhibit CYP3A4 activity noncompetitively, with a Ki value of 1"><entity charOffset="56-57" id="DDI-PubMed.25858508.s15.e0" text="AL" /></sentence><sentence text="09 μM in HLMs" /><sentence text=" Moreover, activity of CYP2C19 could also be inhibited by AL with IC50 of 36"><entity charOffset="58-59" id="DDI-PubMed.25858508.s17.e0" text="AL" /></sentence><sentence text="82 μM" /><sentence text=" Other CYP450 isoforms were not markedly affected by AL"><entity charOffset="53-54" id="DDI-PubMed.25858508.s19.e0" text="AL" /></sentence><sentence text=" The inhibition was also validated by in vivo study of mice" /><sentence text=" AL significantly decreased mRNA expression of Cyp2c and 3a family"><entity charOffset="1-2" id="DDI-PubMed.25858508.s21.e0" text="AL" /></sentence><sentence text="" /><sentence text="The study indicates that herb-drug interaction should be paid more attention between AL and drugs metabolized by CYP3A4"><entity charOffset="85-86" id="DDI-PubMed.25858508.s23.e0" text="AL" /></sentence><sentence text="" /></document>